Subscribe to receive this FREE daily commentary directly in your email
4/23/22
STOCKS – NVDA, ADBE, SQ, XBI
MACRO – SPY, QQQ, VIX
- RTM: Looking For New Lows [Daily Update]
- RTM – ISRG [Internal Notes]
- RTM: Powell Targets Financial Conditions [Daily Update]
- RTM: Bonds Hidden Message? [Daily Update]
- Visa And Mastercard Inflation Hedges? [Video]
The week ending April 22 was brutal. The S&P 500 fell by nearly 2.75%, but it was much worse than that. Because the index rallied hard to start the week, which typically happens following a monthly options expiration date. But then Powell unleashed hell when he noted that a 50 bps rate hike was on the table for the FOMC meeting in May, and stocks dropped.
From the April 21 high, the S&P 500 dropped 5.3% in nearly a straight vertical line down. It was even worse for the NASDAQ 100 QQQ ETF, which fell by almost 6.5%. One of the most breathtaking declines I can recall since March 2020.
Many people are calling for a bottom on social media, but I don’t see how that is possible, not if you listen to what the Fed is saying, and Powell made that very clear this past week. The Fed wants financial conditions to tighten and probably wants those financial conditions to be above neutral so that financial conditions harm the economy. History tells us there is no way stocks can thrive in that environment. I have gone over this same topic for months now (FREE DOWNLOAD), warning since the summer of last year that the Fed would tighten financial conditions and stocks would suffer.
On top of this, the Fed is planning to reduce its balance sheet by around $100 billion a month; this too will work to tighten financial conditions and reduce margin levels in the market. The Fed has yet to even start reducing the balance sheet, and still, since October, margin levels have fallen sharply. On top of that, reserve balances held by banks at the Fed have already started to decline, also negatively affecting margin levels.
The further margin levels fall due to tight financial conditions and reductions in reserve balances, the more pressure there will be on the equity markets.
I have been following these relationships for some time, and just this past week, there has been a massive reduction in reserve balances when the Treasury took money out of its general account that is held at the Fed. This led to reserves dropping to $3.3 trillion from roughly $3.8 trillion in one week. This decline should significantly impact equity prices over the next two weeks. Fighting the Fed at this point doesn’t seem wise.
S&P 500 (SPY)
The S&P 500 is now trading below its 10-month exponential moving average, which in the past has signaled a reversal of the trend for the index. The month isn’t over yet, but the index needs to rally back to 4386 to be above that moving average by month-end.
Additionally, there is still that unfilled gap on the index, around 4,170, which is likely to be filled soon.
VIX
The VIX did move up on Thursday and Friday, which means the odds of a Vanna rally early next week have increased. Although I would not expect a rally to last because investors will need to keep buying puts heading into the FOMC meeting on May 4. It seems possible that the S&P 500 rallies back to the 4,330s before the next leg down starts.
Nvidia (NVDA)
Nvidia continues to fall and has now dropped below $200 for the first since October. The shares are now down more than 40% from their all-time high, and I don’t think the selling is over yet. The next logical resting place for Nvidia comes around the low $ 180s.
Adobe (ADBE)
Adobe made a new closing low on Friday and is one of the stocks to be watched. If it continues to drop, it tells us that the next leg in the S&P 500 and NASDAQ will result in a lower low. The next big area of support for Adobe doesn’t come until the low $ 390s, after that there is a long way down into the $320s.
PayPal (PYPL)
If PayPal, Shopify, and other stocks are all trading below their pre-pandemic highs, why isn’t Block? For that to happen, it has to drop below $83.
Biotech ETF (XBI
It doesn’t look good if the biotech sector is a sign of things to come for the broader market. The XBI Biotech ETF is now trading not only at pre-pandemic levels; it is trading approaching its March 2020 lows. That’s how bad it has gotten for that sector and an indication of the market’s risk appetite.
This week coming week will not be easy. Rest up
Mike
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and, unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.
Subscribe to receive this FREE daily commentary directly in your email
This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.
A Waiting Game...
Mott Capital's Market Chronicles 18 hours ago